Kornimate/medical-research-clean huggingface dataset:
ticagrelor removal study using cytosorb® 300 ml device during cpb in patients undergoing emergent cardiothoracic surgery

Conditions: Acute Coronary Syndrome

Summary: the aim of cytation is to demonstrate intra-operative removal of ticagrelor by cytosorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring cpb, using platelet reactivity to adenosine diphosphate (adp) as a pharmacodynamics surrogate measure of ticagrelor levels in blood.


Eligibility criteria:
inclusion criteria: * signed informed consent * males and females aged ≥18 years * patients treated with ticagrelor * emergency coronary artery bypass graft (cabg) surgery * cardiothoracic surgery requiring cpb ≤24 hours following the last dose of ticagrelor exclusion criteria: * any cardiothoracic surgery \>24 hours after last dose of ticagrelor * resuscitation * any pre-operative coagulopathy unrelated to ticagrelor or standard of care (soc) to undergo surgery with cpb * sepsis (according to sepsis 3.0 definition) * malignant tumor * left ventricular ejection fraction (lvef) \< 20% * history or presence of significant pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurologic, or psychiatric disease which, in the opinion of the investigator, increases risk to the patient or could confound the results of the study * presence of end-stage renal disease or currently receiving renal replacement therapy * patients with a history of major organ transplantation * patients in acute sickle cell crisis * patients concurrently requiring immunosuppressive therapy, with the exception of corticosteroids, or who are profoundly immune suppressed (e.g. cd4 \< 200 or neutropenia with anc \< 1000/μl) * women of childbearing potential with a positive pregnancy test performed during the current admission or who are lactating. women are considered not of child bearing potential if they have been sterilized at least 6 months prior to the study or if they are post-menopausal, defined as amenorrhea for at least 12 months

Keywords: cardiopulmonary bypass cpb ticagrelor removal cytosorb platelet reactivity mea platform test intensive care medicine hemadsorbtion extracorporeal blood purification coronary artery bypass grafting cabg cardiac surgery aortic valve replacement mitral valve replacement
evaluation of ultrasonic neuroma size with residual limb pain in above-knee amputees

Conditions: Neuroma Amputation

Summary: background: the formation of neuromas, a fusiform swelling of a nerve or nerve ending, is a well documented response to limb amputation. likewise, residual limb pain (rlp), pain felt from the remaining portion of the amputated limb, is common among amputees. neuromas are found in more than 90% of lower extremity amputations, of which 30-50% are pain-generating for the patient . and while surgical techniques reveal the commonly held belief that neuroma formation is one of the causal drivers behind rlp, there has been no study to demonstrate that the two events - namely the magnitude of neuroma formation and the magnitude of pain experienced by amputees - are correlated. if this correlation, or lack thereof, were elucidated with the use of ultrasonography, this would provide the preliminary data which could lead to further studies in neuroma minimization and/or proliferation. objective: this study seeks to use ultrasonography (us) to quantify the degree to which neuroma size and the nature of surrounding tissue correlate with the experience of rlp in trans-femoral amputees. setting and subjects: this study will enroll 30 trans-femoral amputees, male and female, who are over the age of 18. the study will take place in the ohsu orthopaedic outpatient clinic, and ohsu imaging department. intervention: none. this is an observational clinical study in which we will characterize the sciatic nerve/neuroma and surrounding tissue using ultrasound. measurements: we will use us to measure the cross sectional area of the neuroma at its widest point and compare this to the cross section of the same neuron at the lesser trochanter. furthermore, we will describe the morphology of the neuroma. to quantify the subject's pain experience we will utilize the questionnaire for persons with transfemoral amputation (q-tfa), trinity amputation \& prosthetic experience scale (tapes), visual analog scale (vas), and the short form 36 (sf-36). analysis: the statistical analysis will employ a pearson correlation coefficient and linear regression analysis.


Eligibility criteria:
inclusion criteria: * greater than 18 years old * a trans-femoral amputee * more than one year post-amputation * has worn a prosthesis within the last year exclusion criteria: * subject also diagnosed with diabetes * subject also diagnosed with peripheral vascular disease * subject also diagnosed with peripheral neuropathy * subject with spinal cord, head, or nerve root injury

Keywords: trans-femoral amputation
the effect of human albumin infusion on vegf levels in women at risk for ovarian hyperstimulation syndrome

Conditions: Ovarian Hyperstimulation Syndrome

Summary: this research study was designed to look at the effect of human albumin transfusion on circulating levels of vascular endothelial derived growth factor (vegf), a protein that is believed to be responsible for the syndrome of ovarian hyperstimulation. patients have been asked to participate because they are identified as at risk for the ovarian hyperstimulation syndrome (ohss), a potentially serious complication of in vitro fertilization. it has been established that the onset of ohss may be preventable by the infusion of albumin at the time of egg retrieval; however, we do not know by what mechanism albumin works. as we know the pathogenesis of ohss is related to vegf released from the ovaries, we believe human albumin may serve to "bind up" this vegf and prevent it from causing its harmful effects. the purpose of this study is to evaluate the effect of albumin infusion on blood and urine vegf levels in these patients.


Eligibility criteria:
inclusion criteria: * infertile patients undergoing in vitro fertilization with or without icsi * estradiol \> 3000 pg/ml at the time of hcg administration * \>/= 20 follicles seen during ultrasound monitoring * patients with polycystic ovarian syndrome exclusion criteria: * patients with only one ovary * patients with medical contraindication to human albumin (hypersensitivity, hypervolemia, cardiac insufficiency, hypertension, esophageal varices, pulmonary edema, severe anemia, renal failure)
dry eye in upper eyelid surgery: muscle versus fat removal

Conditions: Eye Disorders

Summary: the aim of this study is to compare the effects of two different surgical techniques (orbicularis oculi excision and orbicularis oculi + fat excision) applied in upper blepharoplasty surgery on dry eye and to evaluate the effects of these techniques on ocular surface health. 142 patients (71 patients in each group) who met the inclusion and exclusion criteria between 01.05.2025 and 31.12.2025 in mersin city education and research hospital eye diseases clinic will be included in this study. this study is a prospective, survey study and aims to evaluate the effects of two different surgical techniques (orbicularis oculi excision only and orbicularis oculi + fat excision) applied in upper blepharoplasty surgery on postoperative dry eye symptoms. the study will be conducted on patients who are currently scheduled for upper blepharoplasty surgery and no additional surgical procedures or interventions will be applied to the patients. data collection will be done by a survey study and retrospective recording of routine clinical examinations. the collected data will be used to analyze the differences in dry eye parameters between the two surgical techniques. osdi scores, but times, oxford staining degrees, schirmer test results and visual acuity values will be compared at pre- and postoperative time points. differences between groups will be analyzed by one-tailed independent samples t-test and p\&lt;0.05 will be considered significant. these analyses will be performed to determine the effect of surgical techniques on dry eye symptoms.


Eligibility criteria:
inclusion criteria: 1. patients who are currently undergoing upper eyelid blepharoplasty 2. patients between the ages of 18-80 3. patients with a 6-month postoperative follow-up 4. patients without a preoperative dry eye diagnosis 5. patients who have not had previous eyelid surgery 6. those who signed the informed consent form/written consent form 7. patients with complete treatment and follow-up files exclusion criteria: 1. being under 18 and over 80 2. having a history of previous eyelid surgery 3. diabetics 4. having diseases that cause dry eyes such as sjögren, systemic lupus erythematosus 5. having dry eye disease before surgery
european trial of adjuvant oral glucocorticoid pulse therapy in pemphigus

Conditions: Pemphigus

Summary: by this study, the investigators want to test if the value of adjuvant pulse glucocorticoid therapy for pemphigus can be determined by comparing an experimental arm (dexamethasone pulse therapy, prednisolone, and azathioprine) with a control arm (placebo pulse therapy, prednisolone, and azathioprine). the investigators will determine the rate of complete remission with dexamethasone pulse therapy; the time needed for complete remission; and the duration of remission, and compare these data with those of the placebo arm.

pemphigus is a severe chronic dermatological disease which appears to be incurable. oral glucocorticoid now forms the cornerstone of treatment. from previous uncontrolled studies it has been suggested, that the use of high dose intravenous glucocorticoid pulse therapy may lead to complete remission without further therapy. prospective placebo-controlled studies of adjuvant pulse therapy for pemphigus are lacking. this prospective, multi-centre, randomised, double-blind, placebo-controlled trial assesses the efficacy and steroid-sparing effect of oral high-dose glucocorticoid pulse therapy as adjuvant added to the standard combination therapy of prednisone and azathioprine in the treatment of pemphigus vulgaris, in terms of complete remission rate (primary endpoint), initial control, disease control, and adverse events. in the experimental arm glucocorticoid pulse therapy is given, comprising monthly pulses with 300mg oral dexamethasone on three consecutive days. in addition the patients receive daily prednisone and azathioprine treatment, the latter dose adjusted to the thiopurine-methyltransferase level. in the control arm the glucocorticoid pulse therapy is replaced double blindly by monthly oral placebo capsules on three consecutive days. in addition the patients receive the same daily combination schedule with prednisone and azathioprine as in the experimental arm. this study design requires 30 patients in each arm, with one year follow-up. only new patients with pemphigus vulgaris and/or pemphigus oris are included.

Eligibility criteria:
inclusion criteria: * new patients with diagnosis of pemphigus vulgaris exclusion criteria: * diagnosis of pemphigus different from vulgaris type * current use of adjuvant treatment other than azathioprine. a wash out period of at least 2 weeks is required before inclusion is acceptable. * presence of contra-indications for the use of high dose steroids * no availability for follow-up. * concomitant diseases treated with oral steroids. * glucocorticoids administered for pemphigus vulgaris longer than two months. * presence of contra-indications for the use of azathioprine.

Keywords: pemphigus dexamethasone glucocorticoids pulse therapy randomised placebo-controlled
an evaluation of protective effects of opalseal™ against early dental decay in orthodontic patients

Conditions: Cavities of Teeth

Summary: fluoride is very effective in preventing dental decay (cavities) when applied in the form of a varnish on tooth surfaces. the purpose of this study is to verify if fluoride-releasing primer (opalseal) offers more protection against early dental decay (cavity) compared to conventional primer (transbond xt) during treatment with braces.

primers are a type of 'glue' routinely used in orthodontics to attach brackets (metallic components) to the teeth. opalseal is a fluoride-releasing primer that has the potential to reduce cavities in patients receiving braces. orthodontic patients are at particular risk of developing two types of early carious lesions (decay): 1. around the brackets called white spot lesions and 2. along the sides of the teeth after slenderization procedure called inter-proximal reduction (ipr). our research questions are: 1. can opalseal offer protection against white spot lesions (wsl) around the brackets? 2. can opalseal offer protection against decay on the sides of teeth following ipr?

Eligibility criteria:
inclusion criteria: * patients age 10 and older seeking treatment at the vcu orthodontics clinic who require extraction of at least 2 teeth for orthodontic purposes * such teeth should be free of any developmental defects exclusion criteria: * patients under 10 years of age * patients with defective teeth * those who cannot provide consent/assent or not able to follow research protocols * protected population (prisoners)
registry with information about colitis ulcerosa and familial adenomatous polyposis patients

Conditions: Colitis,Ulcerative; Adenomatous Polyposis Coli; Reservoir, Ileoanal

Summary: the purpose of this registry is to collect information about patients in which a pouch has been created to improve in the future the quality of the surgery of the pouch.

to improve the quality of the surgery of the pouch created in cu and fap patients, the following information will be collected: patients characteristics, operative data, postoperative outcome and functional postoperative recovery.

Eligibility criteria:
inclusion criteria: * colitis ulcerosa or familial adenomatous polyposis patients with ipaa exclusion criteria: * no

Keywords: registry colitis ulcerosa (cu) familial adenomatous polyposis(fap) ipaa
a study of safety, tolerability, and the effects two nd-l02-s0201 have on the body

Conditions: Fibrosis

Summary: the purpose of this study is to evaluate the safety, tolerability, and the effects two nd-l02-s0201 have on the body


Eligibility criteria:
inclusion criteria: * subject is in good health, as determined by the investigator * subject consumes an average of no more than 2 alcoholic drinks per day within the 6 months before administration of study drug * subject has serum calcium and parathyroid hormone (intact) within the limits of the normal range of the laboratory exclusion criteria: * subject has a disease or condition (medical or surgical) which, in the opinion of the investigator, may compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, or central nervous systems; or other conditions that may interfere with the absorption, distribution, metabolism, or excretion of nd-l02-s0201 solution, or that may place the subject at increased risk * subject has a history of bone disease, including osteoporosis and osteomalacia, paget's disease of bone, or a history of unexplained fractures or fractures after minimal trauma * subject has abnormal laboratory values considered to be clinically significant by the investigator other protocol inclusion/exclusion criteria may apply
manual lymphatic drainage before and after total knee replacement, a single-center observer-blinded randomized controlled trial

Conditions: Total Knee Arthroplasty; Manual Lymphatic Drainage; MLD; Rehabilitation; Knee Osteoarthritis

Summary: the aim of this observer-blinded randomized controlled trial is the evaluation of the influence of manual lymphatic drainage (mld) on the outcome of patients receiving total knee replacement (tka).


Eligibility criteria:
inclusion criteria: * total knee arthroplasty (tka) exclusion criteria: * venous insufficiency * bmi \> 38 * vascular disease
role of chatgpt in vestibular schwannoma management

Conditions: Vestibular Schwannoma

Summary: previous studies have demonstrated that patients frequently undergo significant decision conflict regarding major medical decisions in otolaryngology. there lack validated tools available for decision support for patients. while limited evidence has demonstrated that clinical decision support tools can alleviate decision conflict for patients with diagnosis in otolaryngology, conversational language models were not employed in these studies and may provide additional benefit in this context. this study seeks to evaluate the efficacy of using chatgpt, a conversational language model with basic clinical knowledge, in alleviating decision conflict for patients with new diagnosis in otolaryngology. for this pilot study, vestibular schwannoma, a benign tumor that develops on the vestibular nerve with known clinical equipoise, has been chosen for the initial study diagnosis. efficacy will be evaluated by comparison of responses to the decisional conflict scale (dcs) and satisfaction with decision (swd) scores between a group given training in chatgpt and a control group (no chatgpt training).


Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosed with vestibular schwannoma * have access to internet-enabled device that is compatible with chatgpt exclusion criteria: * \< 18 years old * patient without diagnosis of vestibular schwannoma * patient does not have access to internet-enabled device * patient who declines study participation
does style of pre-sedation instructions improve patient outcomes in ambulatory anesthesia for oral and maxillofacial surgery?

Conditions: Anesthesia Outcomes; Anesthesia Complication; Anesthesia and Procedure Related Time Intervals; Anesthesia Recovery Period; Anesthesia, Intravenous; Anesthesia Induction

Summary: this randomized controlled trial aims to evaluate the impact of a brief guided visualization exercise on anesthesia-related outcomes in oral and maxillofacial surgery in patients scheduled for ambulatory anesthesia in the oral and maxillofacial surgery clinic. researchers will compare these patients, who will receive the guided visualization exercise in addition to standardized pre-operative instructions, to patients who will only receive the standardized pre-operative instructions. the following outcomes will be measured for both groups: * a seven-point anesthesia experience survey * face-legs-activity-cry-consolability (flacc) scores at three points in time during the anesthetic - during local anesthesia, during surgery, and fifteen minutes after surgery has concluded * amount of medications used during the sedation * length of sedation


Eligibility criteria:
inclusion criteria: * subjects within ages 8 to 70. * subjects planned for ambulatory intravenous sedation in the oral and maxillofacial surgery clinic. * ability to understand verbal english or understand instructions using a sign-language or voice interpreter of their native language. exclusion criteria: * subjects who cannot understand the instructions, even with an interpreter (extremes of age, cognitive impairments, severe psychiatric disease that may affect participation) * subjects not undergoing intravenous sedation (oral sedation, nitrous oxide, local anesthesia) * subjects undergoing anesthesia in other environments (gastrointestinal suite, operating rooms, interventional radiology)

Keywords: anesthesia experience survey ambulatory anesthesia intravenous sedation guided visualization pre-sedation instructions anesthesia outcomes oral &amp; maxillofacial surgery (omfs) face, legs, activity, cry, consolability (flacc)
a study of pitolisant in patients with prader-willi syndrome

Conditions: Prader-Willi Syndrome

Summary: this is a phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with prader-willi syndrome. the primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (eds) in patients ≥6 years of age with prader-willi syndrome. secondary objectives include assessing the impact of pitolisant on: * irritable and disruptive behaviors * hyperphagia * other behavioral problems including social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech

the study will consist of an up to 45-day screening/baseline period, a double-blind treatment period, and an optional open-label extension period. after completion of all baseline assessments, patients who meet all eligibility criteria will be randomized 1:1 to receive once daily pitolisant or matching placebo. during the double-blind treatment period, in-person visits will be at day 29, day 57, and day 77. patients who do not elect to enter the open-label extension period will have follow-up visits 15 days and 30 days after the final dose of study drug. during the optional open-label extension period, in-person visits will be at day 113, day 260, and day 441. patients will have follow-up visits 15 days and 30 days after the final dose of pitolisant.

Eligibility criteria:
inclusion criteria: * genetically confirmed diagnosis of pws * excessive daytime sleepiness * has a consistent parent/caregiver (preferably the same person throughout the study) who is willing and able to complete the required study assessments. * in the opinion of the investigator, the patient/parent(s)/caregiver(s)/legal guardian(s) are capable of understanding and complying with the requirements of the protocol and administration of oral study drug. exclusion criteria: * has a diagnosis of sleep apnea (osa, csa) that is not adequately controlled * has a diagnosis of hypersomnia due to another sleep/medical disorder * participation in an interventional research study involving another investigational medication, device, or behavioral treatment within 30 days or 5 half-lives (whichever is longer) of the investigational medication prior to screening

Keywords: pitolisant excessive daytime sleepiness irritable and disruptive behaviors prader-willi syndrome
effect of acute normovolemic haemodilution on allogenic transfusion needs in laparotomy

Conditions: Surgery

Summary: this study is aimed to determine if acute normovolemic hemodilution (anh), an established blood conservation technique, reduces the requirement for allogeneic blood transfusion in operations with prediction of surgical bleeding over 20% of estimated blood volume (ebv)

allogeneic blood transfusion is often done during surgery to save life- threatening conditions. blood conservation is a method that can reduce peri-operative allogeneic blood transfusion. this study has been conducted on 34 patients underwent laparotomy surgery with bleeding more than 20% of ebv. after being informed concent, research subjects were randomized into two groups: anh (conducted anh) and control group (without anh). after starting general anesthesia, the anh group was withdrawing blood based on gross formula. restoration of circulated volume was instituted by infusion of colloids. in control group, the operation was started right after the induction of anesthesia. the monitoring of blood pressure, heart rate, the amount of bleeding, total fluid, urine production, hemoglobin concentration and number of allogenic transfusion were recorded.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for laparotomy under general anesthesia with potentially surgical bleeding \> 20% of ebv * asa physical status i - ii * hemoglobin level before surgery \> 11 g / dl for men and \> 10 g / dl for women exclusion criteria: * impaired coagulation (inr\> 1.5 and / or platelet count \<100,000) * active infection * disruption of metabolic liver * received anti fibrinolytic drugs

Keywords: acute normovolemic hemodilution allogeneic transfusion